轻度认知障碍的生物学标志物研究进展

高松; 张敏; 陆媛

doi:10.16766/j.cnki.issn.1674-4152.003562

轻度认知障碍的生物学标志物研究进展

doi: 10.16766/j.cnki.issn.1674-4152.003562

高松^{1, 2},
张敏¹,
陆媛^3, ,

1.
同济大学医学院全科医学系，上海 200090
2.
上海市浦东新区合庆社区卫生服务中心，上海 201201
3.
同济大学附属杨浦医院全科医学科，上海 200090

基金项目:

上海市卫生健康委员会科研课题面上项目 201940495

上海市浦东新区卫生健康委员会优势全科医学学科建设项目 PWYq2020-03

详细信息

通讯作者:
陆媛，E-mail：lussy@126.com

中图分类号: R749.16
计量
- 文章访问数: 48
- HTML全文浏览量: 28
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2023-06-25
- 网络出版日期: 2024-07-22

Research progress on biomarkers of mild cognitive impairment

GAO Song^{1, 2},
ZHANG Min¹,
LU Yuan^{3
, ,}

1.
Department of General Practice, Tongji University School of Medicine, Shanghai 200090, China

摘要

摘要: 轻度认知障碍(MCI)是介于正常衰老和痴呆之间的一种临床过渡状态，被认为是阿尔茨海默病(AD)的临床前阶段。由于阿尔茨海默病病程的不可逆性，且目前临床上尚无可改善病情或延缓疾病进程的有效疗法，因此，MCI的早期发现、早期诊断、早期干预治疗对降低AD的发病率、延缓进展至关重要。对于生物标志物的研究，一方面可以为揭示疾病的病理机制提供依据，另一方面可以为疾病的早期筛查和诊断提供客观证据支持。本文通过对MCI的生物标志物进行综述, 以期为后续MCI确切病理机制的研究、有效治疗方案的探索以及病情客观临床指标的确定提供依据和帮助。本文分别从脑脊液、血液、遗传学等方面对MCI生物标志物的研究进展进行综述，重点对生物标志物(尤其是淀粉样蛋白、磷酸化tau蛋白)在脑脊液以及血液中的研究进展进行分析讨论。不同来源途径的生物学标志物研究各有优缺点，MCI血液生物标志物优势明显，临床转化意义大，具有较好的研究前景。生物标志物的标准化、规范化仍是目前MCI研究领域所需努力的一大方向。
- 轻度认知障碍 /
- 生物标志物 /
- 阿尔茨海默病
Abstract: Mild cognitive impairment (MCI) is a clinical transitional state between normal aging and dementia, which is considered to be the preclinical stage of Alzheimer's disease (AD). Due to the irreversible nature of the course of AD, and the lack of clinically available therapies to improve or delay the disease progression, the early detection, diagnosis and intervention of MCI are crucial in reducing the incidence of AD and delaying its progression. On one hand, research on biomarkers can serve as the foundation for elucidating the pathological mechanisms underlying the disease. On the other hand, it provides objective evidence for early screening and diagnosis. This paper reviewed the research progress of MCI biomarkers from the cerebrospinal fluid, blood and genetics perspectives with a focus on the analysis and discussion advancements in biomarkers (especially amyloid protein, phosphorylated tau protein) found in cerebrospinal fluid and blood. The study of biomarkers from different sources and pathways has their own advantages and disadvantages. MCI hematological biomarkers have significant potential for clinical translation with promising research prospects. The standardization of biomarkers is still a major direction in MCI research field.
- Mild cognitive impairment /
- Biomarkers /
- Alzheimer's disease

HTML全文

参考文献(48)

[1]	PETERSEN R C. Mild cognitive impairment[J]. Continuum (Minneap Minn), 2016, 22(2Dementia): 404-418.
[2]	PETERSEN R C. Mild cognitive impairment: transition between aging and Alzheimer's disease[J]. Neurologia, 2000, 15(3): 93-101.
[3]	ALBERT M S, DEKOSKY S T, DICKSON D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement, 2011, 7(3): 270-279. doi: 10.1016/j.jalz.2011.03.008
[4]	CLIFFORD R J, DAVID A B, KAJ B, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease[J]. Alzheimers Dement, 2018, 14(4): 535-562. doi: 10.1016/j.jalz.2018.02.018
[5]	ZETTERBERG H, PEDERSEN M, LIND K, et al. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years[J]. J Alzheimers Dis, 2007, 12(3): 255-260. doi: 10.3233/JAD-2007-12307
[6]	BUCHHAVE P, MINTHON L, ZETTERBERG H, et al. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia[J]. Arch Gen Psychiatry, 2012, 69(1): 98-106. doi: 10.1001/archgenpsychiatry.2011.155
[7]	STENH C, ENGLUND H, LORD A, et al. Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay[J]. Ann Neurol, 2005, 58(1): 147-150. doi: 10.1002/ana.20524
[8]	HANSSON O, ZETTERBERG H, BUCHHAVE P, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment[J]. Dement Geriatr Cogn Disord, 2007, 23(5): 316-320. doi: 10.1159/000100926
[9]	MA Y, BRETTSCHNEIDER J, COLLINGWOOD J F. A systematic review and meta-analysis of cerebrospinal fluid amyloid and tau levels identifies mild cognitive impairment patients progressing to Alzheimer's disease[J]. Biomedicines, 2022, 10(7): 1713. DOI: 10.3390/biomedicines10071713.
[10]	OLSSON B, LAUTNER R, ANDREASSON U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis[J]. Lancet Neurol, 2016, 15(7): 673-684. doi: 10.1016/S1474-4422(16)00070-3
[11]	HARALD H, KATHARINA B, JENS C P, et al. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer's disease[J]. Archives of Neurology, 2005, 62(5): 770-3. DOI: 10.1001/archneur.62.5.770
[12]	BUERGER K, TEIPEL S J, ZINKOWSKI R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects[J]. Neurology, 2002, 59(4): 627-629. doi: 10.1212/WNL.59.4.627
[13]	JANELIDZE S, STOMRUD E, SMITH R, et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease[J]. Nat Commun, 2020, 11(1): 1683. doi: 10.1038/s41467-020-15436-0
[14]	BARTHELEMY N R, BATEMAN R J, HIRTZ C, et al. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification[J]. Alzheimers Res Ther, 2020, 12(1): 26. doi: 10.1186/s13195-020-00596-4
[15]	LANTERO-RODRIGUEZ J, SNELLMAN A, BENEDET A L, et al. P-tau235: a novel biomarker for staging preclinical Alzheimer's disease[J]. EMBO Mol Med, 2021, 13(12): e15098. DOI: 10.15252/emmm.202115098.
[16]	KANDALEPAS P C, SADLEIR K R, EIMER W A, et al. The Alzheimer's beta-secretase BACE1 localizes to normal presynaptic terminals and to dystrophic presynaptic terminals surrounding amyloid plaques[J]. Acta Neuropathol, 2013, 126(3): 329-352. doi: 10.1007/s00401-013-1152-3
[17]	ZETTERBERG H, ANDREASSON U, HANSSON O, et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease[J]. Arch Neurol, 2008, 65(8): 1102-1107.
[18]	ZHONG Z, EWERS M, TEIPEL S, et al. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment[J]. Arch Gen Psychiatry, 2007, 64(6): 718-726. doi: 10.1001/archpsyc.64.6.718
[19]	VERHEIJEN J H, HUISMAN L G, van LENT N, et al. Detection of a soluble form of BACE1 in human cerebrospinal fluid by a sensitive activity assay[J]. Clin Chem, 2006, 52(6): 1168-1174. doi: 10.1373/clinchem.2006.066720
[20]	ROSEN C, ANDREASSON U, MATTSSON N, et al. Cerebrospinal fluid profiles of amyloid beta-related biomarkers in Alzheimer's disease[J]. Neuromolecular Med, 2012, 14(1): 65-73. doi: 10.1007/s12017-012-8171-4
[21]	HOLSINGER R M, LEE J S, BOYD A, et al. CSF BACE1 activity is increased in CJD and Alzheimer's disease versus[corrected] other dementias[J]. Neurology, 2006, 67(4): 710-712. doi: 10.1212/01.wnl.0000229925.52203.4c
[22]	MULDER S D, van der FLIER W M, VERHEIJEN J H, et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology[J]. J Alzheimers Dis, 2010, 20(1): 253-260. doi: 10.3233/JAD-2010-1367
[23]	CHOURAKI V, BEISER A, YOUNKIN L, et al. Plasma amyloid-beta and risk of Alzheimer's disease in the Framingham Heart Study[J]. Alzheimers Dement, 2015, 11(3): 249-257. doi: 10.1016/j.jalz.2014.07.001
[24]	van OIJEN M, HOFMAN A, SOARES H D, et al. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study[J]. Lancet Neurol, 2006, 5(8): 655-660. doi: 10.1016/S1474-4422(06)70501-4
[25]	ABDULLAH L, LUIS C, PARIS D, et al. Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort[J]. Mol Med, 2009, 15(11-12): 432-437. doi: 10.2119/molmed.2009.00083
[26]	HANSSON O, ZETTERBERG H, VANMECHELEN E, et al. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment[J]. Neurobiol Aging, 2010, 31(3): 357-367. doi: 10.1016/j.neurobiolaging.2008.03.027
[27]	LOPEZ O L, KULLER L H, MEHTA P D, et al. Plasma amyloid levels and the risk of AD in normal subjects in the cardiovascular health study[J]. Neurology, 2008, 70(19): 1664-1671. doi: 10.1212/01.wnl.0000306696.82017.66
[28]	LOVHEIM H, ELGH F, JOHANSSON A, et al. Plasma concentrations of free amyloid beta cannot predict the development of Alzheimer's disease[J]. Alzheimers Dement, 2017, 13(7): 778-782. doi: 10.1016/j.jalz.2016.12.004
[29]	TOSUN D, VEITCH D, AISEN P, et al. Detection of β-amyloid positivity in Alzheimer's disease neuroimaging initiative participants with demographics, cognition, MRI and plasma biomarkers[J]. Brain Communications, 2021, 3(2). DOI: 10.1093/braincomms/fcab008.
[30]	QU Y, MA Y H, HUANG Y Y, et al. Blood biomarkers for the diagnosis of amnestic mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis[J]. Neurosci Biobehav Rev, 2021, 128: 479-486. doi: 10.1016/j.neubiorev.2021.07.007
[31]	SIMREN J, LEUZY A, KARIKARI T K, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease[J]. Alzheimers Dement, 2021, 17(7): 1145-1156. doi: 10.1002/alz.12283
[32]	MIELKE M M, HAGEN C E, WENNBERG A, et al. Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo clinic study on aging[J]. JAMA Neurol, 2017, 74(9): 1073-1080. doi: 10.1001/jamaneurol.2017.1359
[33]	MIELKE M M, HAGEN C E, XU J, et al. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau-and amyloid-positron emission tomography[J]. Alzheimers Dement, 2018, 14(8): 989-997. doi: 10.1016/j.jalz.2018.02.013
[34]	MATTSSON-CARLGREN N, JANELIDZE S, PALMQVIST S, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease[J]. Brain, 2020, 143(11): 3234-3241. doi: 10.1093/brain/awaa286
[35]	PALMQVIST S, JANELIDZE S, QUIROZ Y T, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders[J]. JAMA, 2020, 324(8): 772-781. doi: 10.1001/jama.2020.12134
[36]	JANELIDZE S, MATTSSON N, PALMQVIST S, et al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia[J]. Nat Med, 2020, 26(3): 379-386. doi: 10.1038/s41591-020-0755-1
[37]	MATTSSON N, ANDREASSON U, ZETTERBERG H, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease[J]. JAMA Neurol, 2017, 74(5): 557-566. doi: 10.1001/jamaneurol.2016.6117
[38]	MATTSSON N, CULLEN N C, ANDREASSON U, et al. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease[J]. JAMA Neurol, 2019, 76(7): 791-799. doi: 10.1001/jamaneurol.2019.0765
[39]	PREISCHE O, SCHULTZ S A, APEL A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease[J]. Nat Med, 2019, 25(2): 277-283. doi: 10.1038/s41591-018-0304-3
[40]	LU Y, TAN L, WANG X. Circular HDAC9/microRNA-138/Sirtuin-1 pathway mediates synaptic and amyloid precursor protein processing deficits in Alzheimer's disease[J]. Neurosci Bull, 2019, 35(5): 877-888. doi: 10.1007/s12264-019-00361-0
[41]	GEEKIYANAGE H, JICHA G A, NELSON P T, et al. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease[J]. Exp Neurol, 2012, 235(2): 491-496. doi: 10.1016/j.expneurol.2011.11.026
[42]	XIE B, LIU Z, JIANG L, et al. Increased serum miR-206 level predicts conversion from amnestic mild cognitive impairment to Alzheimer's disease: a 5-year follow-up study[J]. J Alzheimers Dis, 2017, 55(2): 509-520.
[43]	DURAND D, CARNIGLIA L, TURATI J, et al. Amyloid-beta neurotoxicity and clearance are both regulated by glial group Ⅱ metabotropic glutamate receptors[J]. Neuropharmacology, 2017, 123: 274-286. doi: 10.1016/j.neuropharm.2017.05.008
[44]	XIE B, ZHOU H, LIU W, et al. Evaluation of the diagnostic value of peripheral BDNF levels for Alzheimer's disease and mild cognitive impairment: results of a meta-analysis[J]. Int J Neurosci, 2020, 130(3): 218-230. doi: 10.1080/00207454.2019.1667794
[45]	BERTRAM L, TANZI R E. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses[J]. Nat Rev Neurosci, 2008, 9(10): 768-778. doi: 10.1038/nrn2494
[46]	TANZI R E, BERTRAM L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective[J]. Cell, 2005, 120(4): 545-555. doi: 10.1016/j.cell.2005.02.008
[47]	MCKHANN G M, KNOPMAN D S, CHERTKOW H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease[J]. Alzheimers Dement, 2011, 7(3): 263-269. doi: 10.1016/j.jalz.2011.03.005
[48]	LI J Q, TAN L, WANG H F, et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies[J]. J Neurol Neurosurg Psychiatry, 2016, 87(5): 476-484. doi: 10.1136/jnnp-2014-310095